TRT Treatment Options: Injections, Gels, Oral & More

Affiliate disclosure: This educational guide does not recommend a provider and contains no compensated treatment link. Read our full affiliate disclosure.

Direct answer: Testosterone replacement therapy is not one product or one routine. U.S. prescription options include short-acting injections, a weekly subcutaneous autoinjector, a long-acting clinic injection, topical gels or solutions, oral testosterone undecanoate capsules, nasal gel, and implanted pellets. Transdermal patches and buccal systems also appear in FDA materials and historical labeling, although current commercial availability may be limited. None is universally best.

The right format is the one that can be used correctly, monitored correctly, and sustained without creating an avoidable risk or burden. Diagnosis, fertility plans, blood pressure, hematocrit, prostate and urinary history, household exposure risk, daily routine, access, insurance, total cost, and the exact product label all matter more than a clinic’s favorite protocol.

The practical rule: Choose the care plan first and the product second. A format that looks convenient on a sales page can be a poor choice when the diagnosis is incomplete, fertility was never discussed, the product cannot be monitored properly, or the routine does not fit real life.

Scope: This guide covers prescription testosterone treatment formats for adult men being evaluated or treated for hypogonadism. It does not cover nonmedical anabolic-steroid use, bodybuilding cycles, testosterone use by women or children, or gender-affirming hormone care. Those settings involve different goals, dosing, evidence, and monitoring.

────────

TRT treatment options at a glance

Answer: Every testosterone format delivers the same hormone, but it does not deliver it in the same way. The route changes the dosing rhythm, local risks, household precautions, laboratory timing, ease of dose adjustment, procedure burden, and total cost.

This table is a decision map, not a prescription. “Injection,” “gel,” and “oral testosterone” are categories, not interchangeable products. A vial of testosterone cypionate, a weekly subcutaneous autoinjector, a long-acting clinic injection, a 1% gel, a 1.62% gel, and an oral testosterone undecanoate capsule all have different instructions.

For a deeper comparison of the two most commonly discussed formats, read testosterone injections vs. gel.

────────

Before comparing products, confirm that TRT is the right category of treatment

Answer: A treatment-format comparison is premature when low testosterone has not been diagnosed correctly or the cause has not been investigated.

The Endocrine Society guideline recommends diagnosing hypogonadism only when a man has compatible symptoms or signs and unequivocally, consistently low testosterone measured with accurate testing. It recommends confirming the result with a repeat morning fasting total-testosterone measurement and evaluating the cause.

That sequence matters because fatigue, low mood, reduced libido, erectile symptoms, reduced exercise capacity, sleep problems, and body-composition changes are not specific to testosterone deficiency. Obesity, untreated sleep apnea, medication effects, depression, chronic illness, pituitary disease, testicular disease, thyroid problems, undernutrition, excessive training, and other conditions may contribute.

A responsible process separates four questions:

1. Are the symptoms compatible with hypogonadism?
2. Is testosterone consistently low under appropriate testing conditions?
3. Why is it low?
4. Would testosterone replacement provide more likely benefit than harm in this situation?

A clinic that jumps from one screening result to “pick injections or cream” has skipped the most important part of the decision.

Read how to get TRT through a responsible medical process and the complete TRT blood-test guide before treating a product menu as a diagnosis.

Fertility belongs before the format decision

All exogenous testosterone formats can suppress the signals from the brain to the testes, reduce intratesticular testosterone, and reduce or stop sperm production. A gel does not preserve fertility because it is topical. A nasal product does not preserve fertility because it is short-acting. A pellet does not preserve fertility because it is “bioidentical.” The route changes delivery; it does not remove testosterone’s negative feedback on the reproductive system.

The AUA/ASRM male-infertility guideline says testosterone monotherapy should not be prescribed to a man interested in current or future fertility. It also says clinicians may use hCG, selective estrogen receptor modulators, aromatase inhibitors, or combinations in selected infertile men with low testosterone, but the evidence and suitability depend on the diagnosis.

Someone who may want biological children should discuss timing, baseline fertility evaluation, semen testing when appropriate, sperm preservation, and alternatives with a reproductive urologist or another qualified fertility specialist before starting testosterone.

Read the full guide to TRT and fertility.

────────

FDA approval, commercial availability, and compounding are three different questions

Answer: “Prescription testosterone” does not tell you whether the exact product is FDA-approved, currently marketed, covered by insurance, available from the pharmacy, or compounded for an individual patient.

FDA-approved product

An FDA-approved product has product-specific labeling that describes its approved use, dose form, administration instructions, contraindications, warnings, adverse reactions, and monitoring. Approval does not make the product right for every patient, but it gives the clinician and patient a defined label to follow.

Currently available product

A route may appear in FDA class materials or older labels even when a specific brand has been discontinued or is difficult to obtain. Patches and buccal systems are examples where a provider should verify current market availability rather than promising a format from an old comparison chart.

Ask for the exact generic name, brand name when applicable, National Drug Code or product label, dispensing pharmacy, expected availability, and what happens if the product is out of stock.

Compounded product

Compounding can meet a legitimate individual need when an approved product is not medically appropriate. It is not the same regulatory category as an approved brand or generic.

The FDA’s compounding Q&A states that compounded drugs are not FDA-approved and that FDA does not verify each compounded drug’s safety, effectiveness, or quality before marketing. FDA also states that a compounded drug is not an FDA-approved generic.

A clinic offering compounded testosterone should identify:

• The exact formulation and concentration • The prescribing rationale • The dispensing pharmacy • Whether the pharmacy is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, when relevant • The beyond-use date and storage requirements • The administration and transfer precautions • The testing and dose-adjustment plan • What approved option was considered and why it did not meet the patient’s need

“Custom,” “bioidentical,” “pharmaceutical grade,” or “made by an FDA-registered facility” does not mean FDA-approved.

────────

Testosterone injections: several different treatments share one name

Answer: Testosterone injections range from self-administered short-acting products to a weekly subcutaneous autoinjector and a long-acting clinic-only product. They cannot be compared responsibly as one row labeled “shots.”

Short-acting intramuscular testosterone cypionate or enanthate

These oil-based esters—forms designed to release testosterone over time—are what many people mean by injectable TRT. Depending on the exact prescription, the injection may be self-administered after training or given in a clinic.

The practical advantages are straightforward: no daily skin application, no treated-skin transfer to another person, and a schedule that may be easier than a daily product for someone who reliably follows it.

The tradeoffs are equally real:

• Needles, syringes, alcohol pads, and a sharps container may be required. • The prescription must state the dose in milligrams and the volume in milliliters. Confusing the two can create a serious dosing error. • Concentrations can differ. The same volume does not always contain the same amount of testosterone. • The labeled injection route matters. A product labeled for intramuscular use is not automatically equivalent to an approved subcutaneous product. • Injection-site pain, bruising, redness, swelling, bleeding, or infection can occur. • Short-acting injections can create a larger difference between the higher and lower parts of a dosing cycle, especially when intervals are wide. • Testosterone measurement must be interpreted in relation to the dose date and time. • Injectable therapy tends to raise hemoglobin and hematocrit more than topical gel on average, although every format can cause erythrocytosis and individual responses vary.

The DEPO-Testosterone label is one example of product-specific intramuscular labeling. It should not be used as a generic instruction sheet for every injectable testosterone product.

Before accepting an injection prescription, get these details in writing:

• Exact drug and ester • Brand, if any • Concentration in milligrams per milliliter • Dose in milligrams • Corresponding volume in milliliters • Intramuscular or subcutaneous route • Exact schedule • Injection site and technique • Needle and syringe specifications • Single-dose or multidose vial instructions • Storage and travel rules • Safe sharps disposal • Blood-test timing relative to the injection • What to do after a late, missed, spilled, or incomplete dose

A provider that says only “we prescribe 0.5 mL weekly” has not supplied enough information to judge the dose safely. A provider that says only “we use testosterone injections” has not supplied enough information to compare treatment.

Weekly subcutaneous testosterone autoinjector

Not every testosterone injection is intramuscular. XYOSTED prescribing information describes testosterone enanthate in a single-dose autoinjector for subcutaneous use in the abdominal region once weekly.

Its monitoring instructions are also specific: dose adjustment uses a total-testosterone trough measured seven days after the most recent dose after six weeks of dosing, after dose changes, and periodically thereafter.

That does not mean every off-label subcutaneous vial protocol follows the XYOSTED label. The approved device, dose strengths, injection site, trough target, and administration system belong to that product.

The device may be useful for someone who wants a standardized weekly injection without drawing medication from a vial. The tradeoffs include device cost and coverage, injection-site reactions, fixed strength options, blood-pressure monitoring, hematocrit monitoring, and dependence on the exact product remaining available.

Long-acting testosterone undecanoate injection

AVEED prescribing information describes a long-acting intramuscular testosterone undecanoate product given at initiation, four weeks later, and then every ten weeks.

The longer interval can look attractive, but this is not a take-home injection. The U.S. product carries a boxed warning for serious pulmonary oil microembolism reactions and anaphylaxis. It is available only through the AVEED Risk Evaluation and Mitigation Strategy program, and the patient must remain in the healthcare setting for 30 minutes after every injection.

This format may reduce the number of treatment days, but it requires local access to a certified setting, transportation, scheduled observation, and acceptance of a product that remains in the body longer than a daily treatment.

What injections do not prove

An injection is not automatically stronger, more effective, more masculine, more “optimized,” or better for body composition than another format. A high peak soon after a shot is not the same thing as a better clinical response.

The goals are an appropriate testosterone exposure, improvement in the symptoms tied to confirmed hypogonadism, acceptable adverse effects, and a monitoring plan that can detect when the dose or format is wrong.

────────

Testosterone gels and topical solutions: convenient for some, demanding for others

Answer: Topical testosterone avoids needles and can offer daily, more continuous exposure, but it requires a precise routine and serious attention to secondary exposure.

Daily use is part of the treatment

Gels and solutions are usually applied every day. Someone who reliably follows a morning routine may find that easier than injections. Someone who travels, showers at changing times, works in close physical contact, or routinely forgets daily medication may find it harder.

Absorption through skin varies. Missing applications, applying to the wrong site, washing too soon, changing brands, using the wrong number of pumps, or transferring medication before it is absorbed can all change exposure.

A low level on gel should trigger a review of the exact product, technique, adherence, application site, washing interval, and test timing—not an automatic conclusion that “gel never works.”

Gels are not interchangeable

A 1% gel and a 1.62% gel can have different approved application sites, pump outputs, starting doses, titration instructions, and washing restrictions. The milligram amount printed for a topical dose is not directly comparable with the milligram amount in an injection because only part of the skin-applied dose reaches systemic circulation.

For example, current DailyMed labeling for one testosterone gel 1.62% product limits application to specified upper-arm and shoulder sites. A testosterone gel 1% label contains different product-specific directions.

Use the label dispensed with the actual prescription. Do not borrow another person’s instructions or carry over a pump count from a different product.

Secondary exposure is a real household issue

Testosterone can transfer from unwashed or uncovered application skin to another person. Product labels instruct users to wash their hands, allow the product to dry, cover the application site with clothing, and wash the site before anticipated skin contact. Exact precautions and timing come from the product label.

This matters most when a household includes children, a pregnant person, or anyone who may touch the application area. Signs of secondary androgen exposure in a child or another household member warrant prompt medical evaluation.

Someone who cannot reliably prevent contact may be better served by a non-topical format, but that decision should be made with the prescriber rather than by improvising application sites.

Approved gel is not compounded cream

An approved testosterone gel has a product-specific FDA label. A compounded cream may use a different base, concentration, pump, application instruction, and evidence base. The two should not be represented as equivalent simply because both are placed on skin.

Before accepting a topical product, ask:

• Is it FDA-approved or compounded? • What is the exact concentration? • How many milligrams are delivered per pump or packet? • Which skin sites are permitted? • How long must the site dry? • When may the user shower, swim, or wash the site? • What transfer precautions apply? • How should clothing, towels, bedding, and accidental contact be handled? • When will testosterone be measured after starting or changing the dose? • What happens if the level remains low despite correct use?

────────

Oral testosterone: a pill exists, but there is no generic “oral TRT protocol”

Answer: FDA-approved oral testosterone undecanoate capsules exist in the United States. They avoid needles and skin-transfer precautions, but they require a consistent meal-and-dose routine, blood-pressure and hematocrit monitoring, and product-specific laboratory timing.

The word “oral” can cause confusion because older orally active androgens, over-the-counter “testosterone boosters,” prescription testosterone undecanoate capsules, and illicit anabolic steroids are not the same product category.

Modern oral testosterone undecanoate products are absorbed through a formulation designed for oral use. That does not make them risk-free, interchangeable, or equivalent to a supplement.

The three current oral labels use different monitoring instructions

Sources: JATENZO prescribing information, TLANDO prescribing information, and KYZATREX prescribing information.

Those differences make the point: an untimed “total testosterone” result is not enough. A level drawn at the wrong time for the product can lead to a bad conclusion and an unnecessary dose change.

Practical advantages

Oral testosterone may fit someone who:

• Strongly prefers to avoid needles • Cannot safely manage topical transfer precautions • Can take medication with food on a consistent schedule • Has access to the exact product and follow-up testing • Understands that daily adherence still matters

Practical limitations

Oral testosterone may be a poor fit when:

• Meal timing is highly inconsistent • Twice-daily medication is frequently missed • The plan cannot accommodate product-specific blood testing • Blood pressure is uncontrolled or cannot be monitored • The product is unaffordable or not covered • The provider treats all oral products as interchangeable

Current oral testosterone labels include blood-pressure, hematocrit, prostate/urinary, edema, sleep-apnea, and spermatogenesis warnings. Avoiding a needle does not eliminate systemic testosterone risks.

────────

Nasal testosterone gel: no needles, but a frequent daily schedule

Answer: Nasal testosterone is applied inside the nostrils rather than to household-contact skin. Its main tradeoff is a multiple-times-per-day routine and local nasal effects.

NATESTO prescribing information directs administration in each nostril three times daily—morning, afternoon, and evening—six to eight hours apart.

That schedule can work for someone who wants to avoid needles and skin-transfer concerns and who can reliably dose during the day. It can be inconvenient for someone whose work, travel, sleep, or medication habits make midday dosing unrealistic.

The label reports nasal adverse effects such as discomfort, runny nose, nosebleeds, dryness, congestion, scabbing, and changes in smell. Nasal anatomy, prior nasal surgery, chronic nasal disease, and use of other intranasal products may affect suitability and should be discussed with the prescriber.

Do not assume nasal testosterone preserves sperm production. It is still exogenous testosterone, and the fertility discussion still belongs before treatment.

────────

Testosterone pellets: long-lasting convenience with less room to change course

Answer: Pellets trade daily or weekly treatment for an implantation procedure and months of exposure. The convenience is real, but so are the procedure risks and limited dose flexibility.

TESTOPEL prescribing information describes subcutaneous implantation and gives a dosage guideline at intervals of roughly three to six months, adjusted to the individual response.

Why some patients consider pellets

• No daily medication • No home injection supplies • No treated-skin transfer • Long interval between procedures

Why pellets require a different risk conversation

The label reports implantation-site infection and pellet extrusion. Other practical issues include bleeding, bruising, pain, inflammation, wound drainage, scarring, activity restrictions after insertion, and the need for an office procedure.

Pellets are also less flexible than oral medication or short-acting injections. Once implanted, the dose cannot be changed the next morning. The TESTOPEL label states that pellets may need to be removed when complications require testosterone’s effects to be discontinued.

A pellet program should explain:

• Who performs the procedure and where • The clinician’s training and complication process • The exact product and number of pellets • The planned interval and how it is individualized • Preprocedure and postprocedure instructions • Infection and extrusion rates from the provider’s own practice, when available • Who handles a wound problem after hours • How testosterone and hematocrit will be monitored over the full interval • What happens when the dose is too high, too low, or poorly tolerated • Whether removal is available and what it costs • The full first-year cost, including every procedure and laboratory test

“Set it and forget it” is not a responsible description. Long-acting treatment still requires follow-up.

────────

Patches, buccal systems, and less commonly available formats

Answer: Transdermal patches and buccal systems are legitimate delivery concepts, but a comparison page should not imply that every historically approved product remains readily available.

A transdermal patch delivers testosterone through skin over a labeled wear period. The main practical issues include skin reactions, adhesion, visibility, site rotation, and the exact product’s wear instructions.

A buccal system attaches to the gum or inner cheek and releases testosterone through oral tissue. Potential burdens include gum irritation, taste changes, mouth discomfort, adhesion problems, and twice-daily placement for the historical U.S. product.

Availability can change faster than clinical guidance. Before choosing either route, confirm that a currently marketed product can actually be prescribed, dispensed, covered, and monitored. Do not let a provider substitute a compounded product without clearly explaining the regulatory and practical difference.

────────

hCG, clomiphene, enclomiphene, and aromatase inhibitors are not testosterone formats

Answer: These medications may be discussed in low-testosterone care, especially when fertility matters, but they are not forms of testosterone replacement therapy.

hCG

Human chorionic gonadotropin can act like luteinizing hormone at the testes. In selected men—particularly those with specific forms of hypogonadotropic hypogonadism or fertility goals—a specialist may use it alone or with other treatment.

Selective estrogen receptor modulators

Clomiphene and related selective estrogen receptor modulators can increase pituitary signaling in men whose hypothalamic-pituitary-testicular axis can respond. Use in men is often off-label, and benefits, side effects, monitoring, and fertility outcomes vary.

“Enclomiphene” should not be presented as an FDA-approved male-TRT equivalent unless the exact product and approval status can be verified at the time of publication. A compounded enclomiphene prescription is not an FDA-approved generic.

Aromatase inhibitors

Aromatase inhibitors reduce conversion of testosterone to estradiol. They may be used in selected infertility or endocrine situations, but routine suppression of estradiol is not a universal TRT requirement. Estradiol has important roles in male bone and sexual health.

These therapies can be reasonable in the right diagnosis and careless in the wrong one. A provider should explain:

• The diagnosis being treated • Whether the use is FDA-approved or off-label • Why testosterone replacement is or is not being used • What evidence supports the plan • How testosterone, estradiol, semen parameters, symptoms, and adverse effects will be monitored • What result would cause the plan to change

Do not accept “natural TRT,” “fertility-safe TRT,” or “testicular optimization” as a substitute for that explanation.

────────

How the treatment formats differ in the decisions that matter

1. Ability to follow the routine

The best laboratory profile on paper does not help when the routine is repeatedly missed.

• A daily gel may fit a stable morning routine but fail when application is inconsistent. • A twice-daily oral product may fit someone who eats regular meals but fail when doses and meals vary. • A three-times-daily nasal product may fit someone who can dose during the workday but burden someone who cannot. • A weekly injection may be simple for a trained user but stressful for someone with needle fear. • A long-acting injection or pellet may reduce treatment days but requires dependable local appointments.

Choose the routine you can perform correctly—not the one that sounds easiest in a headline.

2. Speed and flexibility of dose adjustment

Daily products can often be stopped or adjusted more quickly under a clinician’s direction. Short-acting injections remain in the body beyond the injection day but are generally easier to modify than a multi-month implant. Long-acting injections and pellets provide less immediate flexibility.

That distinction matters when a patient develops high hematocrit, rising blood pressure, troublesome edema, urinary symptoms, a skin or nasal reaction, mood changes, or another adverse effect.

“Long-lasting” is an advantage only when the product and dose are working well.

3. Peaks, troughs, and timing

Short-acting injections can produce a larger difference between post-dose and pre-dose testosterone. Daily topicals may provide a more continuous exposure pattern but can vary with skin absorption and application behavior. Oral and nasal products create their own product-specific concentration patterns.

A laboratory number is meaningful only when the clinician knows:

• The product • The dose • The administration time • The date and time of the blood draw • Whether doses were missed • Whether the draw occurred at the label-recommended point

A clinic that interprets every testosterone result the same way regardless of route is not monitoring the treatment correctly.

4. Hematocrit

Testosterone can increase red-blood-cell production. Hematocrit is the percentage of blood made up of red blood cells. When it becomes too high, treatment may need adjustment or interruption and other causes should be evaluated.

The American Urological Association testosterone-deficiency guideline reports that injectable testosterone tends to produce the greatest increases in hemoglobin and hematocrit among common formats, although every form can cause erythrocytosis.

Do not treat scheduled blood donation as the entire monitoring plan. A clinician should investigate why hematocrit is rising and decide whether the dose, exposure, route, sleep apnea, smoking, altitude, dehydration, lung disease, or another factor is contributing.

5. Blood pressure

No testosterone route is exempt from blood-pressure monitoring. In February 2025, FDA required class-wide labeling changes after ambulatory blood-pressure studies confirmed increases across testosterone products. FDA simultaneously removed class boxed-warning language about increased major cardiovascular outcomes after reviewing the TRAVERSE trial.

That update should not be flattened into either “TRT is heart-safe” or “TRT causes heart attacks.” It means the major cardiovascular outcome signal studied in TRAVERSE was reassuring while blood-pressure increases and other unresolved risks still require screening and monitoring.

6. Local and household risks

• Injections: pain, bruising, bleeding, infection, device or technique problems, and sharps handling • Gel or solution: skin irritation, transfer to another person, application-site and washing rules • Oral capsules: pill/meal routine and gastrointestinal tolerability, plus systemic warnings • Nasal gel: nasal irritation, bleeding, congestion, scabbing, or smell changes • Pellets: procedure pain, infection, bleeding, extrusion, scarring, and removal risk • Patch: skin reactions and adhesion problems • Buccal system: gum and mouth irritation or adhesion problems

A route-specific problem does not automatically mean testosterone itself is inappropriate, but it may justify a technique review, a different product, or a different treatment category.

7. Fertility

All exogenous testosterone formats can suppress sperm production. The words “topical,” “nasal,” “microdose,” “short-acting,” or “bioidentical” do not create a fertility guarantee.

A person who wants current or future fertility needs a separate plan, not a marketing reassurance.

8. Total cost

Compare the complete first-year cost, not the medication headline.

Depending on the format, the cost may include:

• Initial clinician evaluation • Diagnostic blood tests • Repeat confirmation testing • Cause-focused testing • Medication • Membership fee • Injection supplies and sharps container • Shipping • Office injection fees • Pellet insertion procedures • Follow-up visits • Monitoring labs • Prior-authorization work • Complication care • Cancellation or commitment terms

A cheap vial can become expensive when visits, labs, supplies, and membership fees are excluded. A higher pharmacy price may still be less expensive when insurance covers the drug and the care occurs through an in-network clinician.

Use the complete TRT cost guide before comparing monthly advertisements.

9. Online versus local access

Some formats fit telehealth more easily than others. A licensed telehealth clinician may evaluate and prescribe when federal and state requirements are met, but local care is necessary for procedures such as pellet insertion and for clinic-administered AVEED.

A good online program should not force a format merely because it is easy to ship. A good local clinic should not force a procedure merely because it is profitable.

Compare the care models in online TRT vs. local care.

────────

Monitoring is part of every TRT treatment option

Answer: The route changes how monitoring is timed; it does not remove the need for monitoring.

A complete plan has four stages.

Stage 1: Confirm the diagnosis

This generally includes symptoms or signs plus at least two appropriately collected morning testosterone measurements, interpreted with the assay, reference interval, health context, medications, and cause evaluation.

Stage 2: Establish a baseline

The exact baseline depends on age, history, risk, and guideline framework. It commonly includes blood pressure and a complete blood count or hematocrit. Prostate assessment and PSA testing are individualized according to age, risk, history, symptoms, guideline recommendations, and shared decision-making. Fertility plans should be documented before treatment.

Stage 3: Check exposure and early response

The follow-up testosterone test must be timed to the exact product. The clinician should also ask whether the original symptoms improved, whether the routine is being followed, and whether adverse effects appeared.

Examples of product-specific timing include:

• XYOSTED: a trough seven days after the most recent dose after six weeks of dosing • JATENZO: six hours after the morning dose after at least seven days on the dose • TLANDO: eight to nine hours after the morning dose, three to four weeks after starting • KYZATREX: three to five hours after the morning dose, seven days after starting or adjusting

Those examples are not universal instructions. They demonstrate why the exact label matters.

Stage 4: Continue safety and benefit monitoring

Ongoing follow-up may include:

• Symptoms and functional goals • Adverse effects • Adherence and administration technique • Total testosterone measured at the right point for the product • Hemoglobin and hematocrit • Blood pressure • Prostate or urinary symptoms and age/risk-based assessment • Edema and heart-failure symptoms in at-risk patients • Sleep-apnea symptoms • Acne, oily skin, hair changes, breast symptoms, testicular changes, and sexual symptoms • Fertility goals and semen testing when relevant • Medication interactions • Lipids or other tests when clinically indicated or required by the label

The Endocrine Society guideline recommends evaluating patients after treatment begins to assess response, adverse effects, and adherence.

A provider should be able to answer three questions before the first prescription:

1. What will be checked?
2. When will it be checked relative to this exact product?
3. What result would cause the dose, format, or entire treatment plan to change?

────────

Which TRT option may fit which practical priority?

This is not a personalized recommendation. It is a way to identify the tradeoff that deserves a clinician’s attention.

“I want to avoid needles”

Gel, topical solution, oral testosterone undecanoate, nasal gel, a patch, or a buccal system may avoid needles. The next question is whether daily application, household transfer, meal timing, frequent nasal dosing, skin reactions, mouth reactions, cost, and availability fit better than an injection.

“I do not want a daily routine”

An injection schedule or pellet may reduce daily treatment tasks. A long-acting clinic injection may reduce dose frequency further. The tradeoff is needles or a procedure, less immediate reversibility, local access, and route-specific safety controls.

“I live with young children or a pregnant partner”

A non-topical format avoids treated-skin transfer. That does not make it automatically safest overall; it removes one specific household risk while adding its own burdens.

“My hematocrit is already high”

Elevated hematocrit requires clinical evaluation before treatment. Injectable testosterone tends to raise hematocrit more than gel on average, but switching formats is not the only question. The clinician should consider the testosterone exposure and other causes, including sleep apnea, smoking, altitude, lung disease, dehydration, and other medical conditions.

“My blood pressure is high”

No route bypasses the blood-pressure issue. The exact treatment decision depends on whether hypertension is controlled, the person’s cardiovascular risks, the product label, and whether follow-up is reliable.

“I may want children”

Do not choose among exogenous testosterone formats until fertility has been addressed. Testosterone monotherapy may suppress sperm production regardless of route. A reproductive urologist or fertility-aware endocrinologist may recommend a different evaluation and treatment category.

“I want the lowest total cost”

Generic short-acting injections may have a low medication price, but supplies, labs, visits, and membership fees still count. Insurance formularies may favor one approved product over another. Pellet procedures and brand-only products may create a different cost structure. Compare the entire year.

“I travel often”

Daily products require enough medication and a plan for storage. Injectable testosterone is a Schedule III controlled substance and adds syringes, sharps, documentation, and destination-specific travel considerations. Pellets avoid traveling with medication but cannot be adjusted during the trip. A clinician and pharmacist should help plan rather than relying on airport anecdotes.

“I want the fastest result”

Speed is not the primary treatment goal. A rapid peak or high laboratory number does not prove better symptom improvement and may increase adverse effects. The goal is an appropriate, sustainable exposure and a measurable clinical benefit.

────────

Provider red flags when treatment options are discussed

A provider deserves closer scrutiny when it:

• Recommends a format before confirming the diagnosis • Uses one low or untimed testosterone result as automatic eligibility • Offers the same product and dose pattern to nearly everyone • Cannot name the exact medication, ester, concentration, route, or pharmacy • Describes a compounded product as FDA-approved, a generic, or the same as an approved drug • Calls injections universally stronger or gels universally safer • Says a topical, nasal, pellet, or “microdose” plan will preserve fertility • Cannot explain when testosterone should be measured for the exact product • Does not establish a blood-pressure or hematocrit plan • Treats routine blood donation as the only response to rising hematocrit • Promises “no side effects when monitored” • Markets pellets as maintenance-free • Offers a long-acting injection without explaining the required setting and observation rules • Tells patients to copy doses from social media or another patient’s protocol • Converts injection milligrams directly into gel or oral milligrams • Uses the highest possible testosterone level as the treatment target • Hides laboratory, supply, procedure, shipping, or cancellation costs • Has no clear route for urgent questions, adverse effects, missed doses, or transfer of records

A clinic does not become high quality merely because it offers many formats. It becomes more useful when it can explain why one format fits a particular diagnosis and why another does not.

────────

Questions to ask before accepting a TRT prescription

About the diagnosis

1. Which symptoms or signs support the diagnosis?
2. Were two early-morning testosterone results obtained under appropriate conditions?
3. Were the assay and reference interval considered?
4. Was the cause of low testosterone evaluated?
5. Were reversible contributors addressed?
6. Is a specialist evaluation needed?

About fertility

7. How can this treatment affect sperm production?
8. Should I obtain a semen analysis or preserve sperm before starting?
9. Is testosterone monotherapy appropriate for my reproductive plans?
10. Would a reproductive urologist change the treatment approach?

About the exact product

11. What is the generic and brand name?
12. Is it FDA-approved or compounded?
13. What is the concentration and dose?
14. What route and administration site does the label specify?
15. How often is it used?
16. What food, washing, contact, storage, travel, or disposal instructions apply?
17. Is any part of this plan off-label?
18. Why does this format fit me better than the alternatives?

About monitoring

19. When will the first follow-up occur?
20. When should testosterone be drawn relative to the dose?
21. How will hematocrit and blood pressure be monitored?
22. How will prostate and urinary concerns be handled?
23. What symptoms require a prompt call or urgent evaluation?
24. What result would cause a dose reduction, pause, switch, or stop?

About access and cost

25. Which pharmacy dispenses the product?
26. Is it covered by my plan, and is prior authorization required?
27. What is the complete first-year cost?
28. Are labs, supplies, shipping, procedures, and follow-up included?
29. Is there a commitment period or cancellation fee?
30. What happens when the product is unavailable or I move to another state?
31. How do I obtain my records and transfer care?

────────

Switching from one testosterone format to another

Answer: Switching can be reasonable when the current format is ineffective, poorly tolerated, unsafe, unavailable, unaffordable, or too difficult to use. It should not be done by converting milligrams from one route to another at home.

A safe switch considers:

• The last dose and how long the current product remains active • The reason for switching • Correct use and adherence • Properly timed laboratory results • Hematocrit and blood pressure • Adverse effects • Fertility plans • The starting instructions for the new product • When the first follow-up test should occur • Whether there is a gap or overlap between products

When a format “stops working,” the first step is not always a higher dose. The clinician should check whether the original diagnosis was sound, whether the symptom had another cause, whether the product was used correctly, whether the blood draw was timed correctly, and whether the treatment created a problem that now outweighs the benefit.

Never use leftover medication from the old format after a switch unless the prescriber explicitly directs it.

────────

TRT treatment options: frequently asked questions

What is the best form of testosterone replacement therapy?

There is no universally best form. The best fit is the exact approved or medically justified product that can achieve an appropriate testosterone exposure, improve symptoms tied to confirmed hypogonadism, fit the person’s routine, and remain safe under a real monitoring plan.

Are testosterone injections stronger than gel?

Not in a way that makes one universally better. Injection and gel milligrams cannot be compared directly. Injections may create higher peaks, while gel depends on skin absorption and daily use. Effectiveness is judged by appropriately timed levels, symptom response, adverse effects, and sustainability—not the printed milligram number.

Is gel safer than injections?

Gel avoids needles and usually produces a smaller hematocrit rise than injections on average, but it adds skin-transfer risk and can still raise hematocrit and blood pressure. Neither route is universally safer.

Can TRT be taken as a pill?

Yes. FDA-approved oral testosterone undecanoate products are available. They have different doses and laboratory timing, generally require food, and carry systemic testosterone warnings. They are not the same as over-the-counter testosterone boosters.

Is oral testosterone bad for the liver?

“Oral testosterone” is too broad for a yes-or-no answer. Modern oral testosterone undecanoate products differ from older 17-alpha-alkylated oral androgens associated with serious hepatic toxicity. The current label for the exact product controls, and oral therapy still requires monitoring for blood pressure, hematocrit, adverse effects, and interactions.

Does nasal testosterone preserve fertility?

Do not assume that it does. Nasal testosterone is still exogenous testosterone and can suppress the hormonal signals needed for sperm production. A man interested in current or future fertility needs a fertility-specific plan.

Are testosterone pellets safer because they are implanted by a clinician?

No. Professional insertion does not eliminate systemic testosterone risks, and pellets add procedure-specific risks such as infection, bleeding, bruising, extrusion, and limited dose flexibility.

Is compounded testosterone cream the same as testosterone gel?

No. A compounded cream is not an FDA-approved generic of an approved gel. The base, concentration, delivery, instructions, quality controls, and evidence may differ. The prescription should state exactly what is being compounded and why.

Can I switch from injections to gel or oral testosterone?

Yes, when a licensed clinician creates a transition plan. There is no reliable do-it-yourself milligram conversion between routes. Timing, residual medication, the new label, and follow-up testing all matter.

Do all forms of TRT raise blood pressure?

FDA concluded from required ambulatory blood-pressure studies that testosterone products can increase blood pressure across the class and required labeling changes. The amount varies by product and person, so baseline and periodic monitoring matter.

Do all forms of TRT affect fertility?

All exogenous testosterone formats can suppress gonadotropin signaling and sperm production. The degree and recovery vary, but no testosterone route should be marketed as fertility-safe.

Is a testosterone patch still an option?

Patch technology is a recognized testosterone delivery route, but current commercial availability may be limited. A clinician and pharmacy should verify that a specific marketed product is available before it is presented as a real option.

Which TRT option has the fewest side effects?

No format has the fewest side effects for every person. Each has systemic testosterone risks plus route-specific problems. The better question is which product avoids the risks most relevant to the individual while remaining usable and monitorable.

Is a high testosterone level proof that the treatment is working?

No. Treatment success requires both an appropriate, correctly timed level and meaningful improvement in the symptoms attributed to hypogonadism without unacceptable adverse effects. An excessive level can be evidence that the plan needs correction.

────────

What this page can and cannot tell you

This guide compares treatment formats. It does not choose a product, dose, interval, target level, or provider for an individual.

Important limits:

• Product labels can change. • FDA class pages and individual labels may update on different timelines. • Commercial availability and insurance coverage can change without notice. • State law and telemedicine rules can affect prescribing and dispensing. • A product’s labeled schedule does not apply to a different product. • Compounded formulations do not share one standardized label. • Guideline recommendations require clinical judgment. • Medical history, examination, laboratory results, fertility goals, and other medications can change the decision. • This version has not been reviewed by a named clinician and should not display a medical-review badge.

Verification cadence: Recheck this page when FDA updates testosterone class labeling, a cited DailyMed label changes, the Endocrine Society or AUA updates its guideline, the AUA/ASRM infertility guidance changes, or a treatment format materially enters or leaves the U.S. market. Do not change the visible verification date without repeating those checks.

See our Editorial Standards, Medical Review Policy, Corrections Policy, and Medical Disclaimer.

Found something outdated or incorrect? Send a correction.

────────

The bottom line

Answer: TRT treatment options differ in far more than needles versus no needles. The route changes the routine, concentration pattern, application or procedure risks, household precautions, laboratory timing, flexibility, access, and total cost. It does not remove the need for a correct diagnosis, fertility counseling, blood-pressure monitoring, blood-count monitoring, and follow-up based on clinical benefit rather than a number alone.

A responsible choice follows this order:

1. Confirm hypogonadism with symptoms or signs and reliable repeat testing.
2. Investigate the cause and address reversible contributors.
3. Discuss fertility before any exogenous testosterone.
4. Compare the exact products—not broad categories.
5. Choose a routine the patient can perform correctly.
6. Match laboratory timing to the product label.
7. Monitor symptoms, adverse effects, hematocrit, blood pressure, and individual risks.
8. Reconsider the dose, format, diagnosis, or treatment when the expected benefit does not appear.

The right answer may be a short-acting injection, a daily gel, an oral capsule, nasal gel, a pellet, a less common approved format, or a fertility-focused treatment that is not TRT. It may also be treatment of sleep apnea, obesity, a medication effect, pituitary disease, or another reversible cause before testosterone is prescribed.

Use TRT Provider Guide’s Find My TRT Path tool to organize the care route, testing status, fertility priorities, budget, insurance, and treatment-format questions that apply to your situation. The tool is educational and does not diagnose low testosterone or determine whether TRT is appropriate.

Educational notice: TRT Provider Guide is an independent educational publisher—not a clinic, pharmacy, laboratory, insurer, or medical practice. This page is not medical advice, a diagnosis, personal laboratory interpretation, or a recommendation for a product or dose. Testosterone is a Schedule III controlled substance and requires a valid prescription from an appropriately licensed clinician.

Seek urgent or emergency care for chest pain, sudden trouble breathing, coughing blood, one-sided leg swelling or pain, sudden weakness, facial droop, trouble speaking, fainting, a severe allergic reaction, or another acute emergency. Contact the prescribing clinician promptly for a major rise in blood pressure, severe headache, new neurologic symptoms, worsening urinary symptoms, significant swelling, persistent or painful erection, signs of infection, pellet extrusion, or suspected accidental topical exposure involving a child or pregnancy.

────────

Primary sources

All sources below were accessed and checked on September 2, 2026.

1. Endocrine Society. Testosterone Therapy for Hypogonadism Guideline Resources. March 19, 2018.
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715–1744.
3. Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026.
4. U.S. Food and Drug Administration. Testosterone Information. Updated June 23, 2026.
5. U.S. Food and Drug Administration. FDA Issues Class-Wide Labeling Changes for Testosterone Products. February 28, 2025.
6. American Urological Association. Testosterone Deficiency Guideline. Published 2018; validity confirmed 2024.
7. American Society for Reproductive Medicine. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part II.
8. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
9. DailyMed. DEPO-Testosterone—testosterone cypionate injection.
10. DailyMed. XYOSTED—testosterone enanthate injection. Subcutaneous route, weekly dosing, trough-based adjustment, hematocrit, blood-pressure, and spermatogenesis warnings.
11. DailyMed. AVEED—testosterone undecanoate injection. Pulmonary oil microembolism, anaphylaxis, REMS, schedule, and post-injection observation.
12. DailyMed. Testosterone gel 1.62% prescribing information. Application, transfer, dose adjustment, blood-pressure, and monitoring information.
13. DailyMed. Testosterone gel 1% prescribing information. Product-specific application and washing instructions.
14. DailyMed. JATENZO—testosterone undecanoate capsules. Food, dosing, adjustment, blood-test timing, blood-pressure, and hematocrit information.
15. DailyMed. TLANDO—testosterone undecanoate capsules. Fixed dosing, food, blood-test timing, and continued-use monitoring.
16. DailyMed. KYZATREX—testosterone undecanoate capsules. Food, individualized dosing, and product-specific blood-test timing.
17. DailyMed. NATESTO—testosterone nasal gel. Three-times-daily administration and nasal safety information.
18. DailyMed. TESTOPEL—testosterone pellet. Implantation, dosing interval, infection, extrusion, removal, and dose-flexibility information.
19. U.S. Food and Drug Administration. Best Way to Get Rid of Used Needles and Other Sharps.
20. Electronic Code of Federal Regulations. 21 CFR § 1308.13—Schedule III.